Deltex Medical Regulatory News (DEMG)

8 May 2008 07:01

Deltex Medical Group PLC08 May 2008 Deltex Medical Group plc Third major hospital in southern California implements use of CardioQ-ODM as standard clinical practice 8 May 2008 - Deltex Medical Group plc ("Deltex Medical" or "the Company"), theUK's leading haemodynamic monitoring company, today announces that doctors at athird major hospital in Southern California have embarked on the first phase ofa structured programme to implement routine use of the CardioQ-ODM in surgeryand intensive care. The implementation is being led by anaesthetists from the third largestindependent anaesthetic services provider in the USA in conjunction withsurgeons, intensive care specialists and hospital managers. Anaesthetists from the same group, working in the first hospital to implementroutine use of the CardioQ-ODM, have reported that private insurers, accountingfor approximately sixty-five percent of patients treated in their hospital, havereimbursed all claims made by physicians for the use of the monitor. We alsounderstand that claims have been reimbursed at a level that is at the upper endof user expectations. Deltex Medical's Chief Executive, Andy Hill commented: "While it was planned that anaesthetists at this third hospital would embark onan implementation programme, I believe that the positive experience of theircolleagues and the level of reimbursement they have routinely received hasencouraged a much earlier start than originally envisaged." For further information, please contact:- Deltex Medical Group plc 01243 774 837 Nigel Keen, Chairman njk@deltexmedical.comAndy Hill, Chief Executive ahill@deltexmedical.comEwan Phillips, Finance Director eap@deltexmedical.com Gavin Anderson & Company 0207 554 1400 Deborah Walter dwalter@gavinanderson.co.ukRobert Speed rspeed@gavinanderson.co.uk Charles Stanley Securities 020 7149 6000 (Nominated Adviser)Philip Davies philip.davies@csysecurities.comRussell Cook russell.cook@csysecurities.com Notes for Editors Deltex Medical manufactures and markets the CardioQ-ODM monitor, which usesdisposable ultra-sound probes inserted into the oesophagus to determine theamount of blood being pumped around the body - 'circulating blood volume'.Reduced circulating blood volume is known as hypovolaemia, which leads toinsufficient oxygen being delivered to the organs. This causes medicalcomplications including peripheral and major organ failure which can lead todeath. Hypovolaemia, which is akin to severe dehydration, affects virtuallyevery patient having surgery because of the combined effects of pre-operativestarvation, the impact of the anaesthetic agents and trauma from the surgeryitself. Using fluids and drugs, guided by the CardioQ-ODM, to optimise theamount of circulating blood significantly reduces post-operative complicationsallowing patients to make a faster, more complete recovery and return homeearlier. The CardioQ-ODM incorporates the Company's proprietary software and a smalldiameter, easy-to-use, minimally invasive, disposable oesophageal probe that isused for transmitting and receiving an ultra-sound signal. By using thistechnology, the CardioQ-ODM provides clinicians with the ability tohaemodynamically optimise critically ill patients and those undergoing routinemoderate to major surgery through the controlled administration of fluid anddrugs. Haemodynamic optimisation has been scientifically proven to improve thespeed and quality of patient recovery and reduce hospital stay. There are already over 1,500 CardioQ-ODMs currently in use in hospitalsworldwide and distribution arrangements are in place in over 30 countries. Inaddition, there are currently more than 100 clinical publications on the use ofthe CardioQ-ODM which have repeatedly:- •Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works •Proved that the CardioQ-ODM works in a wide range of surgical procedures •Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients. The SupraQ is an entirely non-invasive device which uses an ultrasound probeheld at the base of the patient's neck to track the flow of blood in the aorta;it presents the same data as the CardioQ-ODM in a similar format and is used fortaking snapshots or monitoring over short periods. This information is provided by RNS The company news service from the London Stock Exchange